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1. Introduction 
Proteomics research involves the identification and characterisation of proteins in order to 
elucidate their function and interactions with other proteins. Since the composition of 
protein mixtures can vary between cell types and can change under certain physiological 
conditions, one aim is often to quantify up- or down-regulation of individual proteins. 
Characterisation of proteomic changes associated with disease often helps to shed light on 
disease mechanisms and identify useful biomarkers and therapeutic targets. It is rarely the 
case that such proteins are either “present” or “absent”, but more likely that they vary in 
abundance to different degrees. It is therefore important to have a sensitive and accurate 
method to measure these changes using an unbiased approach. 
Shotgun proteomics approaches enable identification of proteins that are up-regulated or 
down-regulated under specific conditions and this can be studied in different cell and tissue 
lysates. Isobaric tags for relative and absolute quantification (iTRAQTM) make it possible to 
both identify and quantify proteins simultaneously. iTRAQTM can easily be multiplexed, 
enabling analysis of up to 8 different samples within the same experiment. Our objectives in 
this chapter are to place iTRAQTM (isobaric tags for relative and absolute quantification) in 
context in the history of attempts to bring quantitative studies to proteomics, to explain 
what it can do, to describe in some detail the protocol that we use in this laboratory and to 
illustrate the application of iTRAQTM to medical and clinically-relevant problems, including 
our own work on the proteomic effects of common drug treatments. 
2. A brief history of quantitative proteomics 
Over the last two decades, the emergence of vast genomic databases has completely 
revolutionized the way in which mass spectrometry is used to analyze proteins. Many 
proteins are now well represented in databases, and their annotations are increasingly 
becoming more detailed to include information such as sites of post-translational 
modification. However, this information is only qualitative, which means that differential 
comparisons of protein expression in a perturbed system, with reference to “control” 
proteins in a database, are not yet possible. It is possible, however, to perform parallel 
comparisons of protein expression in different systems using approaches that require 
staining or labeling of proteins.  
www.intechopen.com
 
Integrative Proteomics 
 
348 
The traditional 2-dimensional gel approach, where differentially expressed stained spots are 
excised and identified by mass spectrometry has many limitations. The wide range of 
protein abundance often obscures low abundance proteins and not all types of proteins are 
amenable to gel electrophoresis. Reproducibility is often an issue due to gel-dependent 
variation and this means that quantitation is often difficult and unreliable (reviewed by 
Issaq and Veenstra, 2008).  
Shotgun proteomics methods involving isotope labeling of proteins have been developed 
during the last decade and overcome some of the difficulties associated with quantification 
using gel-based approaches (Wu et al., 2005). One strategy, called SILAC (stable isotope 
labeling by amino acids in cell culture), involves metabolic incorporation of specific amino 
acids into proteins (Ong et al., 2002). Two cell populations are grown in culture media that 
are identical except that one of them contains a 'light' and the other a 'heavy' form of a 
particular amino acid (e.g. 12C and 13C labeled L-lysine, respectively). Both samples are 
combined after the cells are harvested and the proteins are identified by mass spectrometry. 
Metabolic incorporation of the amino acids into the proteins results in a mass shift of the 
corresponding peptides and the ratio of peak intensities in the mass spectrum reflects the 
relative protein abundance. Whilst SILAC is a highly efficient technique, a major drawback 
is that it relies on endogenous labeling of cell lines, so it is not suitable for use with primary 
tissue such as patient samples (e.g. muscle and serum).  
Another strategy, Isotope Coded Affinity Tags (ICAT®), is a cysteine specific, protein-based 
labeling strategy designed to compare two different sample states (Gygi et al., 1999). One 
sample is labeled with a light isotope and the other with a heavy isotope, and then the 
samples are combined and analyzed by mass spectrometry. The ratios of signal intensities of 
the ICAT-tagged peptide pairs are quantified to determine the relative levels of proteins in 
the two samples. The specificity of ICAT reagents for cysteine residues means that the 
approach is sometimes preferred because it reduces sample complexity. However, this also 
creates a drawback in that peptides lacking cysteine residues will not be labeled, so many 
important peptides, including those with post-translational modifications (PTMs) will be 
discarded.  
Isobaric tagging strategies overcome some of the major limitations of isotope tagging. One 
such method was developed by Applied Biosystems (now AB Sciex) and is called iTRAQTM: 
isobaric tags for relative and absolute quantification (Ross et al., 2004). The reagents were 
originally designed for the simultaneous multiplexed analysis of up to 4 samples, but are 
now available as an 8-plex kit (Choe et al., 2007). The iTRAQTM tags react with all primary 
amines of peptides, which means that all peptides are labeled and information about their 
post-translational modifications are retained. The isobaric nature of the tags also means that 
the same peptide from each of the samples being compared appears as a single peak in the 
mass spectrum. This reduces the complexity of the data when compared to isotopic labeling 
strategies where “heavy” and “light” versions of each peptide are detected in each mass 
spectrum.  
3. iTRAQ
TM
: Isobaric tags for relative and absolute quantification 
3.1 iTRAQ
TM
 reagent chemistry 
The iTRAQTM tags are isobaric labels that react with primary amines of peptides including 
the N-terminus and ε-amino group of the lysine side-chain. Each label has a unique charged 
reporter group, a peptide reactive group, and a neutral balance group to maintain an overall 
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mass of 145Da (Figure 1). When a peptide is fragmented by MS/MS fragmentation, the 
iTRAQTM reporter groups break off and produce distinct ions at m/z 114, 115, 116, 117, 118, 
119, 121 and 122. The relative intensities of the reporter ions are directly proportional to the 
relative abundances of each peptide in the samples that being compared. In addition to 
producing strong reporter ion signals for quantification, MS/MS fragmentation of 
iTRAQTM-tagged peptides also produces strong y- and b-ion signals for more confident 
identification. During the design of the iTRAQTM tags, the reporter ion masses were 
carefully selected in order to minimize interference from noise in the low mass region such 
as matrix ions, immonium and fragment ions. This is the reason that the 8-plex reagents skip 
from 119 to 121, since the phenylalanine immonium ion appears at m/z 120. 
 
 
Fig. 1. Structure of the iTRAQTM reagents. 
Each isobaric tag has a unique charged reporter group, a peptide reactive group, and a 
neutral balance group to maintain an overall mass of 145Da.  
3.2 iTRAQ
TM
 work-flow 
The general workflow for an iTRAQTM experiment with 4 tags is shown in Figure 2. Each 
sample is reduced, alkylated, and digested with trypsin. Each set of peptides is then labeled 
with a different one of the 4 (or 8) iTRAQTM tags, pooled, separated by liquid 
chromatography (LC), and the resulting fractions are analysed using mass spectrometry.  
3.3 Digging deeper 
It is not always essential to separate proteins before digestion, but some form of 
fractionation will be needed in order to detect relatively-low abundance components. A 
simple one-dimensional LC separation of peptides from a whole proteome will overwhelm 
the mass spectrometer, and highly abundant peptides will mask detection of others. By 
separating proteins and/or peptides in more than one dimension, it starts to become 
possible to “see the wood for the trees”. Multidimensional protein identification technology 
(MudPIT) is a common technique for whole proteomic analysis such as iTRAQTM 
comparisons, and can be performed off-line or coupled directly to the mass spectrometer 
(Washburn et al., 2001). There are many choices of chromatography techniques, including 
affinity chromatography, ion exchange chromatography, reversed-phase chromatography 
and size-exclusion chromatography.  
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Fig. 2. A general scheme and example data for a 4-plex iTRAQ experiment. 
A. Based on a figure by Zieske (2006), this illustration shows the general scheme of a 4-plex iTRAQ 
experiment. Each of the four sets of peptides are labeled with one of the iTRAQ reagents, mixed 
together and separated by liquid chromatography. In MS analysis, each identical peptide from the four 
sets appears as a single precursor (the iTRAQ balance group ensures that all tags have the same overall 
m/z). Following fragmentation in MS/MS, the iTRAQ reporter ions break off and their relative 
intensities are used for quantification. Each of the four peptides fragments in the same way and give 
rise to b- and y-ions for identification. 
B. shows some example MS and MS/MS data, with an expanded view of the low-mass region of the 
MS/MS spectrum to show the resolved iTRAQ reporter ions.  
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Even after LC separation in two dimensions, we are still only able to scratch the top 10-20% 
of the surface of complex mammalian proteomes using standard instrumentation (Fuller et 
al., 2010). For a global, unbiased view of the proteome, this is a good starting point and can 
often yield clues to follow up further. If particular types of low abundant proteins are of 
interest then enrichment such as subcellular fractionation or immunodepletion of abundant 
proteins will be necessary. 
3.4 Instrumentation 
Matrix-assisted laser desorption ionisation (MALDI) MS/MS and electrospray ionisation 
(ESI) MS/MS are the most common types of mass spectrometer used for iTRAQTM analysis, 
and there have been several comparisons of the two types of instrument for accuracy and 
performance of iTRAQTM quantification. Shirran and Botting (2010) analysed a fixed 
concentration of a six-protein mix and concluded that MALDI MS/MS gave the most 
accurate results. In contrast, two other studies where more complex biological samples were 
analysed concluded that analyses by MALDI and ESI are comparable in terms of accuracy 
and performance (Kuzyk et al., 2009 and Scheri et al., 2008). Whilst it is possible to re-analyse 
archived LC-separated samples by MALDI MS/MS (and so has the potential to yield more 
data), the trade-off is that MALDI analysis usually takes longer than ESI analysis. 
Under standard MS/MS fragmentation (collision-induced dissociation (CID)), an ion trap is 
unable to analyze small product ions because of their low mass cut-off limitation. This 
meant that traditionally, iTRAQTM-based quantification was not possible using an ion trap 
or hybrid instrument containing an ion trap such as the LTQ-Orbitrap. Recently developed 
fragmentation methods now make it possible to perform iTRAQTM-based quantification on 
an LTQ-Orbitrap and include Pulsed Q Dissociation (PQD) (Bantscheff et al., 2008) and 
higher energy C-trap dissociation (HCD) (Zhang et al., 2009). Both fragmentation methods 
are less suited for protein identification at a proteomic scale than CID fragmentation, but 
when combined with CID, HCD allows sensitive and accurate iTRAQTM quantification of 
whole proteomes (Köcher et al., 2009).  
3.5 Accuracy of iTRAQ
TM
-based quantification 
There are many reports in the literature that demonstrate the reliability of iTRAQTM to 
measure changes spanning up to two orders of magnitude accurately on MALDI and ESI 
platforms using low- and high-complexity protein mixtures (Fuller et al., 2010, Scheri et al., 
2008 and Yang et al., 2007). Even in whole proteome protein mixtures, it is possible to 
achieve good correlation between iTRAQTM ratios and those measured biochemically by 
methods such as quantitative western blotting and immunofluorescence microscopy, 
providing appropriate statistical analysis of the iTRAQTM data is carried out (Fuller et al., 
2010).  
There are, however, instances where this is not the case. Low-signal data have higher 
relative variability, irrespective of the instrumentation used (Karp et al., 2010). Since low 
abundance proteins are usually detected with fewer peptides, they are often disregarded 
from datasets when statistics-based filtering approaches are used. Several bioinformatics-
based models have been suggested to help resolve this problem about heterogeneity of 
variance, and include an additive-multiplication error model for peak intensities (Karp et al., 
2010) and IsobariQ software that employs variance stabilizing normalization (VSN) 
algorithms (Arntzen et al., 2011).  
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There are also an increasing number of reports that there is a degree of underestimation of 
iTRAQTM ratios, seen especially with larger changes (Ow et al., 2009, Karp et al., 2010 and 
Ow et al., 2011). “Ratio compression”, as it has been termed, is thought to arise from several 
factors including isotopic contamination and background interference. Providing accurate 
isotope factors are available, it is possible to correct for impurities from chemical enrichment 
and natural isotope abundance in the iTRAQTM reagents using data processing software 
(e.g. this is a standard function in GPS Explorer software, AB Sciex). The bigger problem 
arises from background interference: if two peptides have a very similar m/z and cannot be 
resolved by the mass spectrometer during precursor ion selection, the resulting MS/MS 
spectrum will contain fragment ions and iTRAQTM reporter ions from both peptides. One of 
the two peptides may be identified using this data, but its iTRAQTM ratios may have been 
“diluted” by those arising from the other peptide. This issue is currently very difficult to 
minimise but it has been suggested that it can be partly alleviated using high-resolution 
sample fractionation (Ow et al., 2011). 
4. Example protocol for iTRAQ
TM
 analysis using a MALDI TOF/TOF  
The following protocol is one we routinely use for analysis of iTRAQTM samples on an AB 
Sciex 4800 MALDI-TOF/TOF instrument, but the method could be used with other mass 
spectrometers since we have omitted any instrument-specific information. 
4.1 Cell / tissue extraction 
- Extract cell pellets in 10 volumes of extraction buffer (w/v) containing 6M Urea, 2M 
thiourea, 2% CHAPS and 0.5% SDS in HPLC-grade water.  
- Sonicate extracts briefly to disrupt DNA and leave on ice for 10 minutes, followed by 
centrifugation at 13,000 x g for 10 minutes at 4°C to pellet any insoluble material. 
- To remove detergents that may interfere with iTRAQTM labeling, precipitate the 
proteins by the addition of 6 volumes of ice cold acetone overnight at -20°C.  
- Pellet the acetone precipitates by centrifugation at 13,000 x g for 10 minutes at 4°C and 
then carefully remove and discard the supernatant.  
- Allow the acetone to evaporate and resuspend the pellets in 6M Urea in 50mM 
triethylammonium bicarbonate (TEAB).*  
- Determine the protein concentration in each sample and balance them carefully so that 
all samples contain the same amount of total protein. Each tag is capable of labeling 
100µg of protein but it is best to aim for slightly less than this (i.e. no more than 85µg) to 
allow for protein estimation errors. It is better to have slightly less protein than to have 
unlabeled peptides appearing in the mass spectrometer.  
*It is important to avoid using buffers containing primary amines such as Tris buffers. 
4.2 iTRAQ
TM
 labeling  
- Perform reduction and alkylation steps using the reagents and instructions provided in 
the iTRAQTM labeling kit (AB Sciex). Detailed instructions can be found on the 
iTRAQTM chemistry reference guide, available on the AB Sciex website. 
- Dilute the extracts in 50mM TEAB so that the urea concentration is less than 1M before 
the addition of trypsin.  
- Digest with sequencing grade trypsin (1:20 w/w in 50 mM TEAB) and incubate 
overnight at 37°C.  
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- Dry down digests in a vacuum centrifuge (in order to maximise iTRAQTM labeling 
efficiency the volume of each sample should be less than 50µl). 
- For the iTRAQTM labeling step follow instructions provided with the iTRAQTM reagents 
kit. 
4.3 Dimension I: Strong cation-exchange (SCX) chromatography 
- Pool the iTRAQTM-labeled peptides and make up to a total volume of 2.5mls in SCX 
buffer A (10mM phosphate, pH3 in 20% acetonitrile (MeCN) (Romil, UK)). The volume 
can be adjusted depending on the sample loop size. In order to ensure efficient binding 
to the SCX column, the final pH should as close to pH3 as possible. This can be 
achieved by the addition of orthophosphoric acid, whilst being careful to ensure that 
the overall phosphate concentration is not increased significantly (as this will also affect 
the binding efficiency).  
- The following flow rates and conditions are optimized for use with a polysulfoethyl A, 
SCX column (300A, 5uM (PolyLC))  
 Load the pooled peptides (2.5mls) onto a SCX column at a flow rate of 
400ul/minute.  
 Following sample injection wash the column with SCX buffer A until the baseline 
returns (this usually takes about 10-15 minutes).  
 Run the gradient as follows: 0-50% SCX buffer B (10mM phosphate, 1M NaCl, pH3 
in 20% acetonitrile) over 25 minutes followed by a ramp up from 50% to 100% SCX 
buffer B over 5 minutes. Finally, wash the column in 100% SCX buffer B for 5 
minutes before equilibrating for 10 minutes with SCX buffer A.  
 Collect 400ul fractions during the elution period (this usually yields about 20 
fractions) and dry down completely in a vacuum centrifuge. 
- Once dry, fractions can be stored at -20°C until the next step. 
*Polysulfoethyl A columns work best at ambient temperature so if you have a column oven you should 
remember to turn it off. Use of 0.1% TFA or high concentrations of formic acid in the mobile phase is 
not recommended so it is best to equilibrate the system with SCX buffer A before connecting the 
column. 
4.4 Dimension II: Reversed-phase chromatography 
Prior to mass spectrometry analysis, separate fractions by reversed-phase liquid 
chromatography. The following flow rates and conditions are optimised for use with a 
Pepmap C18 column, 200µm x 15cm (LC Packings).  
- Resuspend fractions in 30µl of RP buffer A (2% acetonitrile, 0.05% TFA in water (Sigma 
Chromasolv plus)). The order of fractions should be randomized in order to minimise 
effects from sample carry-over on the column.  
- Perform reversed-phase chromatography separation of each fraction using the 
following gradient: 
 Load fractions at a flow rate of 3µl/minute  
 10 minutes isocratic pre-run at 100% RP buffer A (0.05% TFA in 2% acetonitrile in 
water),  
 followed by a linear gradient from 0-30% RP buffer B (0.05% TFA in 90% 
acetonitrile in water) over 100 minutes,  
 followed by another linear gradient from 30%-60% RP buffer B over 35minutes.  
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 Wash the column in 100% RP buffer B for a further 10 minutes, before a final 
equilibration step in 100% RP buffer A for 10 minutes.  
 During the elution gradient, spot the eluate at 10 second intervals using a Probot 
(LC Packings) with α-cyano-4-hydroxycinnamic acid (CHCA) at 3mg/ml (70% 
MeCN, 0.1% TFA) at a flow rate of 1.2µl/min. 
4.5 MALDI-TOF/TOF analysis 
Instrument settings will of course vary, depending on the type of MALDI TOF/TOF 
instrument used. Even two identical machines from the same vendor may need to be tuned 
and optimised slightly differently for optimal performance. For this reason, we have just 
highlighted some important general issues to consider, rather than suggesting exact 
instrument settings:  
- Internal standards: MALDI TOF/TOF analysis of fractions from one reversed-phase 
LC run can take many hours and so it is important to be sure that the instrument is 
calibrated for the duration. By spiking a known standard into the MALDI matrix, 
with an internal calibration processing method specified, you can ensure that every 
fraction contains an internal reference. Glu-1-Fibrinopeptide is a common standard of 
choice, but it is important to ensure that you optimise the amount you spike in so that 
it is detectable in MS but not so abundant that it masks detection of your iTRAQTM 
peptides.  
- Ion statistics: in order to get good ion statistics for iTRAQTM quantification it is 
important to acquire enough data from each spectrum. A total of 1000 shots per MS 
spectrum (with no stop conditions) and at least 2500 shots per MS/MS spectrum (no 
stop conditions) should be acquired.  
- CID: The MS/MS acquisition operating mode should specify that collision-induced 
dissociated (CID).  
- Precursor ion selection: it is important to set a limit on the number of precursors 
selected per spot for MS/MS analysis to enable you to get maximum of data out the 
spot, without burning the spot out. The order in which precursor ions are selected and 
analysed is also an important consideration. For an unbiased view of a proteome, a 
common approach is to acquire weaker precursors first (i.e. those with a lower 
signal/noise) as these are harder to get good fragmentation data from when spots start 
to burn out. Another approach is to skip a selected number of the strongest precursors 
in each spot, in an attempt to negate masking of low abundant peptides by those that 
are in high abundance.  
4.6 Bioinformatics 
There are several different software packages for performing database searches with 
iTRAQTM data and many utilize MASCOT as the search engine. Software that supports 
iTRAQTM quantification will have several particular features: the ability to exclude the 
iTRAQTM reporter ion masses from the search, identify spectra with fixed iTRAQTM 
modifications (N-term (iTRAQTM), lysine (iTRAQTM) and methyl methanethiosulfonate 
(MMTS) modification of cysteine residues) and to apply correction factors to the peak areas 
of the iTRAQTM reporter peaks in peptide spectra identified. Although it is possible to 
manually calculate relative quantification, many software packages will also be able to 
perform this function automatically. GPS Explorer (AB Sciex), for example, is able to 
calculate iTRAQTM protein and peptide ratios for all identified peptides in the database 
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search. The ratio is calculated by selecting one tag as the reference mass and applying the 
following calculation: ratio = fragment corrected area / reference corrected area. A 
normalization factor is usually also applied, and can be useful to normalize any deviances in 
iTRAQTM ratios due to unequal total protein in each sample set and impurities in the 
iTRAQTM tags themselves (normalized iTRAQTM Ratio = Ratio / median iTRAQTM Ratio of 
all found pairs). 
4.7 Validation 
Quantitative proteomic experiments such as iTRAQTM are performed in an unbiased fashion 
and are intended to provide us with clues for further study, rather than to provide definitive 
answers. In order to extract useful information from the masses of data that are produced in 
iTRAQTM experiments, it is important to have a system in place to interrogate and validate 
the data carefully. The approach used will depend on the aim of the experiment and the 
type of comparison that is being done (e.g. pair-wise, 4-plex but with samples in duplicate, 
4-plex but with 4 different samples), but some points for consideration are listed: 
- Cut-off values: data can be simplified dramatically by first applying a cut-off to remove 
proteins that are detected with less than a certain number of peptides, and also with less 
than a certain total ion score confidence interval. A good starting point is to apply a 
very stringent filter and reduce if necessary (i.e. discard proteins detected with less than 
95% total ion score confidence interval and less than 2 peptides). The data may then be 
filtered further to leave proteins that up- or down-regulation by a defined  minimum 
amount.  
- Statistics: the iTRAQTM protein ratio is an average ratio, calculated using the individual 
peptide ratios for each peptide used to identify the protein. One inaccurate peptide ratio 
may dramatically skew the average ratio for the whole protein, so for validation, it is 
important to also look closely at the individual peptide ratios for each protein. One way 
to do this is to perform statistical tests that compare normalized peptide ratios from 
each sample in a pair-wise fashion.  
- Biochemistry: providing antibodies are available, iTRAQTM-predicted changes in 
protein levels can be confirmed by biochemical methods such as western blotting, 
ELISA or immunohistochemistry.  
- Mass spectrometry approaches: although they often take time to optimise, high 
through-put mass spectrometry-based assays such as multiple-reaction monitoring 
(MRM) can be especially useful for validating biomarkers, especially when antibodies 
are not available (Anderson and Hunter, 2006). 
5. Applications of iTRAQ
TM
 in medical research  
Since 2005, several hundred papers have been published that describe applications of 
iTRAQTM to many areas of medical research, including, but not limited to: various cancers, 
neurodegenerative disorders, liver and kidney problems, pre-eclampsia, diabetes, host-
pathogen interactions, pancreatitis and autoimmune disorders. The majority of these studies 
were designed to discover biomarkers in order to understand disease mechanisms, to improve 
methods for early and sensitive diagnosis, to identify potential therapeutic targets, or to 
understand the mechanism of action of drugs. A smaller number of studies also attempted to 
identify biomarkers that could be useful for predicting the prognosis of patients with various 
types of cancer (Rehman et al., 2008; Matta et al., 2009; Tripathi et al., 2010). 
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5.1 Examples of clinically-relevant iTRAQ
TM
 applications 
An early, clinically-relevant application of iTRAQTM was in 2005 when DeSouza et al. 
identified nine potential biomarkers for endometrial cancer. In 2007, they performed a much 
larger 40-sample iTRAQTM study in an attempt to verify these earlier findings, and found 
that none of the nine previously identified potential biomarkers had the sensitivity and 
specificity to be used individually to discriminate between normal and cancer samples. They 
did however, find that a panel of three of these proteins: pyruvate kinase, chaperonin 10 and 
α1-antitrypsin, gave good results with sensitivity, specificity, predictive value and positive 
predictive value of 0.95 in a logistic regression analysis (DeSouza et al., 2007). Glen et al. 
(2008) used iTRAQTM to identify tumor regression antigen, gp96, as a highly-significant 
marker to distinguish benign from malignant prostate cancers. Rudrabhatla et al. (2010) used 
iTRAQTM to identify amino-acid residues on neurofilament proteins that were more highly-
phosphorylated in Alzheimer Disease patients, while Abdi et al. (2006) reported potential 
biomarkers in cerebrospinal fluid to distinguish Alzheimer's disease, Parkinson's disease 
and dementia with Lewy body (DLB). The greatest improvement of iTRAQTM over 2D-gels 
is observed with membrane proteins and Han et al. (2008) were able to use it to identify 
potential therapeutic targets for autosomal dominant polycystic kidney disease by 
comparing kidney plasma membranes from wild-type and diseased mouse models. Grant et 
al. (2009) used iTRAQTM to study the effects of aging on the proteome of cardiac left 
ventricles and obtain clues to the mechanism of loss of diastolic function with age. Pendyala 
et al. (2010) used iTRAQTM to show that the vitamin E binding protein, afamin, is down-
regulated after viral infection in a study of HIV-1-associated neurocognitive disorder 
(HAND). Although serum samples present a problem for iTRAQTM because of high 
concentrations of a few major proteins, the work of Dwivedi et al. (2009) illustrates how this 
was overcome in a study of the proteomic effects of anti-TNF-alpha treatment of rheumatoid 
arthritis patients. These examples illustrate the wide variety of applications of iTRAQTM to 
the most common of all human health problems. 
5.2 Considerations when comparing patients  
With adequate care, meaningful iTRAQTM comparisons of diseased versus control tissues 
are possible, as illustrated in the previous section. However, iTRAQTM comparisons of 
patient-derived material such as skin fibroblasts, serum, CSF, saliva and other tissue types 
present additional problems: in particular, they may display differences due to the age, sex 
or genetic background of the original donors, rather than specifically due to a genetic 
mutation or disease state. For example, Miike et al. (2010) used iTRAQTM to show that there 
are gender differences in serum protein composition and Truscott et al. (2010) used 
iTRAQTM analysis of human lenses to show that protein-membrane interactions change 
significantly with age. Our own work on the inherited neuromuscular disease, spinal 
muscular atrophy (SMA), can also be used to illustrate some of the issues associated with 
comparing patient-derived material. The widely-used GM03813 primary skin fibroblasts 
from a spinal muscular atrophy (SMA) patient (Coriell Cell Repositories) have a genetic 
mutation that causes a large reduction in the levels of SMN protein. Using iTRAQTM 
labeling technology, followed by two-dimensional liquid chromatography and MALDI 
TOF/TOF analysis, we quantitatively compared the proteomes of a variety of SMA and 
control skin fibroblast lines. Comparison of SMA patient fibroblasts with an unrelated 
control of similar age showed that the largest differences reflected their different genotypes 
(i.e. HLA and MHC antigens). This was largely overcome by comparison with fibroblasts 
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from the child’s mother, an unaffected SMA carrier (GM03814). However, myogenic cells 
present in one primary cell line (GM03813) but not the other resulted in an apparent 
increase in the myoblast-specific protein, desmin in the SMA cells (Figure 3). This 
observation enabled us to obtain a myoblast-free fibroblast population for further studies by 
immortalizing and cloning this primary cell line (Fuller et al, 2010). 
 
 
Fig. 3. A non-homogeneous patient cell line gave false positive iTRAQTM results.  
Peptides from an SMA patient cell line were analysed in duplicate (labeled with 114 and 115 
iTRAQ tags) and compared to a control cell line, also analysed in duplicate (labeled with 116 
and 117 iTRAQ tags). An example MS/MS spectrum is shown for a peptide identified as the 
muscle-specific protein, desmin. The image inset on the top left is an expanded MS/MS 
spectrum showing that only the 114 and 115 reporter ions were detected. The suspicion that 
the SMA patient cell line contained myogenic cells, absent from control cells, was confirmed 
by immunofluorescence microscopy with an anti-desmin antibody (green in the inset 
image).  
5.3 Proteomic effects of drug treatments 
In-vivo studies that monitor the therapeutic effect of drugs on patients over time are very 
complicated to design and involve considering many factors such as: the time of day tissue 
sample is taken, change in diet, infection and secondary effects caused by the disease or 
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aging. However, an iTRAQTM comparison of a single cell line, with and without a drug, is a 
much more straightforward general approach to understanding the mechanisms of action of 
drugs and their side-effects. Wang et al. (2010) used this approach to examine the effect of 
the beta blocker Carvedilol in vascular smooth muscle cells and found 13 proteins that were 
altered in expression. Another example is the work of Bai et al. in 2010, when they used 
iTRAQTM to look at the effects of the anti-coagulation drug warfarin on HepG2 cells and 
identified two proteins, DJ-1 and 14-3-3 Protein, that were altered in expression.  
We recently used this approach to identify possible side-effects of drugs for spinal muscular 
atrophy (SMA) (Fuller et al., 2010). Valproate is commonly used as an anticonvulsant in 
epilepsy and as a mood stabilizer, but its long-term side-effects can include bone loss. As a 
histone deacetylase (HDAC) inhibitor, valproate has also been considered for treatment of 
SMA. Using iTRAQ labeling, we performed a quantitative comparison of the proteome of an 
SMA skin fibroblast cell line, with and without valproate treatment. The most striking 
change was a reduction in collagens I and VI, while over 1000 other proteins remained 
unchanged. The collagen-binding glycoprotein, osteonectin (SPARC, BM-40) was one of the 
few other proteins that were significantly reduced by valproate treatment. Collagen I is the 
main protein component of bone matrix and osteonectin has a major role in bone 
development, so the results suggest a possible molecular mechanism for bone loss following 
long-term exposure to valproate. An example MS/MS spectrum showing reduction of a 
collagen I peptide after treatment valproate is shown in Figure 4. 
 
 
Fig. 4. Reduction of collagen I after treatment with valproate  
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Peptides from an SMA patient cell line treated with valproate were analysed in duplicate 
(labeled with 116 and 117 iTRAQ tags) and compared to the same cell line without valproate 
treatment, also analysed in duplicate (labeled with 114 and 115 iTRAQ tags). An example 
MS/MS spectrum is shown for a peptide identified as collagen. The image inset on the top 
left is an expanded MS/MS spectrum showing that the 116 and 117 iTRAQ reporter ions 
were much lower in intensity than the 114 and 115 iTRAQ reporter ions. Biochemical studies 
confirmed that collagen I is reduced after treatment with valproate (Fuller et al., 2010). 
5.4 Bringing biomarkers to the bedside 
Although there are many reports in the literature using iTRAQTM to identify potential 
biomarkers of disease, very few biomarkers ever get fully validated to the stage where they 
can be used in a clinical setting to benefit patients. The low rate of transition from the 
laboratory to the clinic is something that is seen with biomarkers in general, and not just 
those identified by iTRAQTM or other quantitative proteomic approaches. In order for a new 
biomarker to be introduced into routine clinical practice, a slow and detailed process is 
required to obtain evidence that it is robust, precise and reproducible, in addition to 
demonstrating that it will improve patient management and outcome, and have audit and 
cost benefits (reviewed in detail by Sturgeon et al., 2010).  
6. Summary and future prospects 
Without a doubt, iTRAQTM labeling of peptides has had a significant impact on the 
development of quantitative proteomics over the last 8 years. The ability to multiplex and 
analyze up to 8 samples within the same experiment adds flexibility to the experimental 
design without complicating MS data analysis. In 2008, Thermo Fisher in-licensed an 
isobaric mass tagging technology called TMT, which can be multiplexed to allow analysis of 
up to 6 samples, further confirmation of the wide acceptance of this technique.  
The discovery of new biomarkers will help us to understand disease mechanisms and 
prognosis better, to improve methods for early and sensitive diagnosis, to identify 
therapeutic targets, or to understand the mechanism of action of drugs. Although iTRAQTM 
has been very useful for potential biomarker discovery, issues regarding analytical and 
experimental variability need to be addressed before the benefit of iTRAQTM reaches routine 
analysis in the clinical laboratory. With further developments to address issues affecting 
accuracy of iTRAQ quantification and improving data analysis tools, medical research may 
benefit greatly from iTRAQ-based quantitative proteomics over the coming years. 
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